CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Interferon Gamma Release Assay for the Identification of Latent Tuberculosis Infection in People with Previous Bacille Calmette-Guérin Vaccination: Clinical Utility, Cost-Effectiveness, and Guidelines

Last updated: August 31, 2020
Project Number: RB1513-000
Product Line: Rapid Response
Research Type: Device
Report Type: Summary of Abstracts
Result type: Report

Question

  1.  What is the clinical utility of the interferon gamma release assay for identifying latent tuberculosis infection in people with previous Bacille Calmette-Guérin vaccination?
  2. What is the cost-effectiveness of the interferon gamma release assay for identifying latent tuberculosis infection in people with previous Bacille Calmette-Guérin vaccination?
  3. What are the evidence-based guidelines regarding the identification of latent tuberculosis infection in people with previous Bacille Calmette-Guérin vaccination?

Key Message

One non-randomized study was identified regarding the clinical utility of the interferon gamma release assay for identifying latent tuberculosis infection in people with previous Bacille Calmette-Guérin vaccination. In addition, one evidence-based guideline was regarding the identification of latent tuberculosis infection in people with previous Bacille Calmette-Guérin vaccination. No relevant economic evaluations were identified regarding the cost-effectiveness of the interferon gamma release assay for identifying latent tuberculosis infection in people with previous Bacille Calmette-Guérin vaccination.